TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer

Abstract Background Whereas the genomic landscape of endocrine‐resistant breast cancer has been intensely characterized in previously treated cases with local or distant recurrence, comparably little is known about genomic alterations conveying primary non‐responsiveness to endocrine treatment in lu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Isabel Grote, Stephan Bartels, Leonie Kandt, Laura Bollmann, Henriette Christgen, Malte Gronewold, Mieke Raap, Ulrich Lehmann, Oleg Gluz, Ulrike Nitz, Sherko Kuemmel, Christine zuEulenburg, Michael Braun, Bahriye Aktas, Eva‐Maria Grischke, Claudia Schumacher, Kerstin Luedtke‐Heckenkamp, Ronald Kates, Rachel Wuerstlein, Monika Graeser, Nadia Harbeck, Matthias Christgen, Hans Kreipe
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
breast cancer
endocrine proliferative response
Ki67
preoperative endocrine therapy
TP53
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/2c544d649b024c5bbd721b91d7f7c740
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/2c544d649b024c5bbd721b91d7f7c740

Ejemplares similares